Results from two parallel trials show Cosentyx (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms1Safety
GW Pharmaceuticals and Otsuka begin the first US phase II/III dose-ranging trials of Sativex in patients with advanced cancer who experience break-through pain
Patients with persistently controlled atopic dermatitis continued to experience stable and low disease activity after receiving reduced dosages of dupilumab, according to a study published in Allergy.These findings show that patient-centered dosing regimens can be successful, Lotte S. Spekhorst, MD, of the department of dermatology and allergology and National Expertise Center for Atopic
Almirall, S.A. (OTC:LBTSF) Q1 2022 Earnings Conference Call May 9 2022 4:00 AM ET Company Participants Carlos Gallardo Piqué - Chairman and President Gianfranco Nazzi - Chief Executive.